Express Scripts Reports Specialty Drug Spending Steadily Rising, And Pipelines Show More To Come
This article was originally published in Pharmaceutical Approvals Monthly
Not only are specialty drugs “the fastest-growing segment of drug spend,” but the pharmacy benefits manager Express Scripts predicts that specialty drug spend will account for 40% of U.S. drug spend by 2014.
You may also be interested in...
The roll-out of Pfizer Inc.’s new personalized non-small cell lung cancer therapy Xalkori blends right in with the prevailing trends in cancer drug launches, proving that six-figure pricing now seems to be the new black in oncology.
Companion diagnostics and biomarkers were the watchwords of the recent ASCO meeting as the cancer community braces for a sea change in treatment. But as more targeted drugs and companion diagnostics make it through the clinical and regulatory arenas, payers will have to grapple with managing the more complex real-world use of these therapies.
The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.